CN113372412B - Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof - Google Patents
Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof Download PDFInfo
- Publication number
- CN113372412B CN113372412B CN202110387572.XA CN202110387572A CN113372412B CN 113372412 B CN113372412 B CN 113372412B CN 202110387572 A CN202110387572 A CN 202110387572A CN 113372412 B CN113372412 B CN 113372412B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polydopamine
- bone tumor
- bone
- composite particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the field of research and development of biological medicines, and particularly relates to a cell-targeted polypeptide for treating bone tumor, and a preparation method and application thereof. The polypeptide has a structure shown in a formula I; the formula I is Dm-X-Rn-C, wherein m is the number of aspartic acid, and m is more than or equal to 6 and less than or equal to 10; n is the number of arginine, n is more than or equal to 6 and less than or equal to 10; the X is a polypeptide fragment that can be recognized and cleaved by MMPs. The polypeptide-modified polydopamine nano-particle with the metal organic framework as the core is loaded with antitumor drug adriamycin, so that the targeting effect can be obviously enhanced, and the toxic and side effects of the drug can be reduced.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a cell targeting polypeptide for treating bone tumor and a preparation method and application thereof.
Background
Malignant bone tumor is a common tumor which is difficult to cure, and is still a great clinical problem. Surgery and chemotherapy are the primary methods of clinical treatment of bone tumors. Surgery can extend the life cycle of bone tumor patients, but surgical margins or small lesions can lead to tumor recurrence. Chemotherapy is a commonly used postoperative adjuvant therapy in the treatment of bone tumors. Chemotherapy drugs used clinically usually adopt a systemic administration method, and lack targeting, so that effective treatment concentration cannot be achieved at bone tumors, and the chemotherapy effect is poor. In addition, chemotherapy has serious side effects and is easy to generate drug resistance. The bone microenvironment provides fertile soil for the recruitment, survival and development of tumor cells. The tumor cells in the bone microenvironment secrete cytokines to stimulate the generation of osteoclasts, the mature osteoclasts absorb bone matrixes to release growth factors, the growth of tumors is promoted, a malignant cycle is formed between the proliferation of the tumor cells and the bone absorption, and the bone microenvironment also provides a barrier for the clinical chemotherapy of malignant bone tumors. This is because stromal cell-derived factor-1 and interleukin-6 produced by bone marrow stromal cells mediate the homing, survival and proliferation of tumor cells, while integrin-mediated adhesion sequesters tumor cells in this protective environment. This "barrier" effect makes it difficult for tumor targeting molecules to further target bone tumor cells. Photothermal therapy has been considered as a very promising approach for tumor therapy, and Polydopamine (PDA) nanoparticles are a class of nanoparticles with high photothermal conversion efficiency and excellent biocompatibility, but their non-specific distribution in vivo limits further applications. Doxorubicin (DOX) is a commonly used antineoplastic drug, but its serious toxic side effects such as cardiotoxicity limit its further use. Therefore, it is very important to develop an effective and stable nano-carrier with bone tumor cell targeting effect and simultaneously capable of reducing toxic and side effects of the drug.
Disclosure of Invention
In view of the above disadvantages of the prior art, the present invention aims to provide a cell-targeted polypeptide for treating bone tumor, a preparation method and a use thereof, which are used for solving the problem that the safety and the effectiveness of bone tumor cell-targeted drugs in the prior art cannot be considered at the same time.
To achieve the above objects and other related objects, the present invention includes the following technical solutions.
In a first aspect of the invention, there is provided an isolated polypeptide having a structure according to formula i:
Dm-X-Rn-C is shown as formula I,
in the formula I, m is the number of aspartic acid, and m is more than or equal to 6 and less than or equal to 10; n is the number of arginine, n is more than or equal to 6 and less than or equal to 10, and X is a polypeptide fragment which can be recognized and cut by MMP.
The polypeptide as described above, wherein m is 8 and n is 8.
The polypeptide according to the above, wherein the amino acid sequence of X is selected from any one of the following:
the application also discloses a composite particle modified by the polypeptide, wherein the composite particle is a polydopamine or polydopamine nano-composite particle modified by the polypeptide; the polydopamine nano-composite particle takes a metal organic framework as an inner core and takes polydopamine as an outer layer.
According to the composite particle, the size of the polydopamine nano-composite particle is 80-200 nm.
According to the composite particle, the metal organic framework is polydopamine and Mn 2+ And Co 3+ A hybrid material with intramolecular voids formed by coordination bond self-assembly.
According to the composite particle, the molar ratio of the polypeptide to the polydopamine or polydopamine nano-composite particle is (5-100): 1.
according to the composite particle, the preparation method of the polydopamine nano-composite particle comprises the following steps: mn (COO) 2 ·4H 2 O、K 3 [Co(CN) 6 ]And dopamine hydrochloride in the presence of an alkaline solvent.
The composite particle as described above, wherein the solvent is ethanol or an ethanol aqueous solution.
The composite particles described above, mn (COO) 2 ·4H 2 O、K 3 [Co(CN) 6 ]And dopamine hydrochloride in a molar ratio of 1 (1-3): (1-3).
The invention also discloses a preparation method of the composite particle, and the polypeptide is mixed with the polydopamine or polydopamine nano-composite particle.
The application also discloses the application of the polypeptide and the composite particle as shown in the specification as bone tumor cell targeting drug carriers or in the preparation of bone tumor treatment drugs.
The application also discloses a carrier of the bone tumor cell targeted drug, wherein the carrier comprises one or two of the polypeptide and the composite particle. Due to metal ions such as Mn contained in the composite particles 2+ The MRI weighted signal of the bone tumor can be effectively enhanced, so that the polydopamine nanocomposite particle is an MRI contrast agent of the bone tumor, and is very suitable for photothermal therapy or photothermal-chemotherapy synergistic therapy of the bone tumor.
The application also discloses a bone tumor cell targeted pharmaceutical composition, which at least comprises:
an effective component for treating bone tumor and a carrier, wherein the carrier is modified by one or two of the polypeptide and the composite particle.
According to the pharmaceutical composition, the active ingredient for treating bone tumor is adriamycin.
The bone tumor in the present application includes primary bone tumor and secondary bone tumor. Primary bone tumors include: osteosarcoma, ewing's sarcoma, fibrosarcoma, etc. Secondary bone tumors are tumors that metastasize to bone from tumors that grow elsewhere in the body. The method comprises the following steps: breast cancer, prostate cancer, liver cancer, lung cancer, kidney cancer, bladder cancer, and the like.
Compared with the prior art, the invention mainly has the following beneficial effects:
1. the prior art can only target bones or tumor cells independently, and the nanoparticles cannot fall off from the bones due to the single bone targeting, so that the potential toxicity exists. Stromal cell derived factor-1 and interleukin-6 produced by bone marrow stromal cells mediate homing, survival and proliferation of tumor cells, while integrin-mediated adhesion sequesters tumor cells in this protective environment. This "barrier" effect makes it difficult for individual tumor targeting molecules to further target bone tumor cells, and is prone to off-target. The oligomeric aspartic acid sequence at the front end of the bone tumor cell targeting peptide designed and synthesized by the invention can be targeted to a bone damage interface of a bone tumor, then the polypeptide fragment of the middle X is cut by matrix metalloproteinase MMP secreted by the bone tumor, and a cell-penetrating peptide fragment with the tail end consisting of oligomeric arginine is exposed, so that the capacity of photothermal nanoparticles entering the bone tumor cell is improved by the cell-penetrating peptide, and the targeting of the bone tumor cell is finally realized. The polypeptide can successfully penetrate through a bone microenvironment to provide a 'barrier' for bone tumor cells, and a high-efficiency bone tumor cell targeting effect is realized.
2. The polypeptide is synthesized with cysteine at the tail end, and the cysteine contains a sulfhydryl group with reactivity, so that the bone tumor cell targeting peptide is easy to modify on the surfaces of various nanoparticles.
In a word, the polypeptide-modified polydopamine nanoparticle taking the metal organic framework as the core is loaded with the anti-tumor drug such as adriamycin, so that the targeting effect can be obviously enhanced, and the toxic and side effects of the drug can be reduced.
Drawings
Fig. 1 is a transmission electron microscope image of the bone tumor targeting peptide modified polydopamine nanoparticle complex obtained in example 1.
Fig. 2 shows the element distribution of the scanning electron microscope for the combination of the polydopamine nanoparticle composite modified by the bone tumor targeting peptide obtained in example 1 and hydroxyapatite.
Fig. 3 is a live imaging diagram of the polydopamine nanoparticle complex modified by the bone tumor targeting peptide obtained in example 1.
Fig. 4 is a nuclear magnetic resonance imaging diagram of the small animal of the polydopamine nanoparticle complex modified by the bone tumor targeting peptide obtained in example 1.
Detailed Description
The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention. Test methods in which specific conditions are not specified in the following examples are generally carried out under conventional conditions or under conditions recommended by the respective manufacturers.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any number between the two endpoints are optional unless otherwise specified in the invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition to the specific methods, devices, and materials used in the examples, the invention may be practiced using any method, device, and material that is similar or equivalent to the methods, devices, and materials described in examples herein, in addition to those described in prior art practice and the description herein.
Unless otherwise indicated, the experimental methods, detection methods, and preparation methods disclosed herein all employ techniques conventional in the art of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related arts. These techniques are well described in the literature, and may be found in particular in the study of the MOLECULAR CLONING, sambrook et al: a LABORATORY MANUAL, second edition, cold Spring Harbor LABORATORY Press,1989and Third edition,2001; ausubel et al, current PROTOCOLS IN MOLECULAR BIOLOGY, john Wiley & Sons, new York,1987and periodic updates; the series METHODS IN ENZYMOLOGY, academic Press, san Diego; wolffe, CHROMATIN STRUCTURE AND FUNCTION, third edition, academic Press, san Diego,1998; METHOD IN ENZYMOLOGY, vol.304, chromatin (P.M. Wassarman and A.P. Wolffe, eds.), academic Press, san Diego,1999; and METHODS IN MOLECULAR BIOLOGY, vol.119, chromatography Protocols (P.B.Becker, ed.) Humana Press, totowa,1999, etc.
The applicant in the application provides a separated polypeptide and unexpectedly discovers that the polypeptide can be used for preparing a medicament for treating bone tumor related diseases, can enhance the targeting effect of the medicament, simultaneously reduces the using amount of active ingredients of the medicament such as adriamycin so as to reduce the toxic and side effects of the adriamycin, can entrust a polypeptide synthesis company to prepare and obtain the polypeptide through chemical synthesis, and the polypeptide has an amino acid sequence shown as a formula I,
Dm-X-Rn-C is shown as formula I;
in the formula I, m is the number of aspartic acid, and m is more than or equal to 6 and less than or equal to 10; n is the number of arginine, n is more than or equal to 6 and less than or equal to 10, and X is a polypeptide fragment which can be recognized and cut by MMP.
In the above, when the values of m and n are less than 6, there is no way to form electron aggregation, and the targeting ability is lost; above 10, the polypeptide chain is too long, self-assembling folds are produced, targeting is not favored, and the targeting effect is optimal for m and n being 8.
The polypeptide also contains an amino acid sequence that can be recognized and cleaved by MMP, and the amino acid sequence of fragment X of the polypeptide satisfying all the conditions described above is shown in Table 1.
TABLE 1
| SEQ ID NO. | |
| 1 | KCQGWIGQPGCK |
| 2 | CQGWIGQPGC |
| 3 | QGWIGQPG |
| 4 | CQGWIGQPGCK |
| 5 | KCQGWIGQPG |
| 6 | |
| 7 | GWIGQPGCK |
| 8 | GWIGQP |
The polypeptide designed and synthesized by the invention is a bone tumor cell targeting peptide, the oligomeric aspartic acid sequence at the front end of the polypeptide can be firstly targeted to a bone damage interface of a bone tumor, then the middle X section is cut by MMP secreted by the bone tumor, and a cell-penetrating peptide fragment with the tail end consisting of oligomeric arginine is exposed, so that the capacity of photothermal nanoparticles entering the bone tumor cell is improved by the cell-penetrating peptide, and the targeting of the bone tumor cell is finally realized. The polypeptide can successfully penetrate through a bone microenvironment to provide a 'barrier' for bone tumor cells, and a high-efficiency bone tumor cell targeting effect is realized.
As the polypeptide has the characteristics, the applicant uses the polypeptide as a carrier of an effective component of a bone tumor cell targeting medicament. The polypeptide modified polydopamine or the polypeptide modified polydopamine nano-composite particles are used in photothermal therapy or chemotherapy or photothermal-chemotherapy synergistic therapy of bone tumors and serve as carriers of active ingredients of bone tumor cell targeted drugs.
The polydopamine nano-composite particle takes a metal organic framework as an inner core and takes polydopamine as an outer layer. The size of the polydopamine nano-composite particle is 80-200 nm. Preferably, the metal organic framework is polydopamine and Mn 4+ And Co 3+ A hybrid material with intramolecular voids formed by coordination bond self-assembly.
The application discloses a bone tumor cell targeted pharmaceutical composition, which at least comprises: an effective component for treating bone tumor cells and a pharmaceutically acceptable carrier, wherein the carrier is modified by one or two of the polypeptide and the composite particles. More specifically, the pharmaceutical composition can be various known active ingredients for treating bone tumor, such as adriamycin.
The preparation method of the polydopamine nano-composite particle comprises the following steps: mn (COO) 2 ·4H 2 O、K 3 [Co(CN) 6 ]And dopamine hydrochloride in the presence of an alkaline solvent. The solvent can be selected according to actual needs, and can be ethanol or ethanol water solution. Preferably, mn (COO) 2 ·4H 2 O、K 3 [Co(CN) 6 ]And dopamine hydrochloride in a molar ratio of 1 (1-3): (1-3).
In order to further verify the above findings and effects, the following experiments and characterization were carried out in the present application for further explanation.
The following examples of the present application specifically use polypeptides wherein m and n are both 8, such polypeptides being:
D 8 -KCQGWIGQPGCK-R 8 -C, noted BTTP.
Example 1
The preparation method of the poly-dopamine nanocomposite particle in the embodiment is as follows:
9.05mg Mn(COO) 2 ·4H 2 o was dissolved in 10ml of 75% ethanol, 10mg of dopamine hydrochloride was then added, and pH =8.5 was adjusted using 1M ammonia water until dopamine hydrochloride was completely dissolved. The mixed solution is magnetically stirred for 30min at 30 ℃, and then 16.6mgK is added 3 [Co(CN) 6 ]And 10mL of 75% ethanol, and the mixed solution was magnetically stirred at 30 ℃ for 24 hours. And centrifuging the reaction product at 12000rpm for 20min, and repeatedly centrifuging and washing the reaction product with deionized water for three times to obtain the poly-dopamine nano composite particles. (notation M @ P)
The preparation method of the bone tumor cell targeted drug carrier in the embodiment is as follows:
the polypeptide and the polydopamine nanocomposite particle synthesized above were mixed at a molar ratio of 20. (record as TM @ P)
The preparation method of the bone tumor cell targeted pharmaceutical composition in this example is as follows:
and (2) mixing the carrier with 0.1mg/mL adriamycin dimethyl sulfoxide solution, wherein the molar ratio of the polydopamine nano particles to the adriamycin is 1. (as TM @ P/DOX)
Example 2
The preparation method of the polydopamine nanocomposite particles in the embodiment is as follows:
18.1mg Mn(COO) 2 ·4H 2 o was dissolved in 10ml of 75% ethanol, then 5mg of dopamine hydrochloride was added, and pH =8.5 was adjusted using 1M ammonia water until dopamine hydrochloride was completely dissolved. The mixed solution is magnetically stirred for 30min at 30 ℃, and then 8.3mgK is added 3 [Co(CN) 6 ]And 10mL of 75% ethanol, and the mixed solution was magnetically stirred at 30 ℃ for 24 hours. And centrifuging the reaction product at 12000rpm for 20min, and repeatedly centrifuging and washing the reaction product with deionized water for three times to obtain the poly-dopamine nano composite particles. (record as M @ P)
The preparation method of the bone tumor cell targeted composite particle in the embodiment is as follows:
mixing the bone tumor cell targeting peptide and the polydopamine nanocomposite particle according to a molar ratio of 100. (Note as TM @ P)
The preparation method of the bone tumor cell targeted pharmaceutical composition in this embodiment is as follows:
and (2) mixing the carrier with 0.1mg/mL adriamycin dimethyl sulfoxide solution, wherein the molar ratio of the polydopamine nano particles to the adriamycin is 1. (as TM @ P/DOX)
Example 3
The preparation method of polydopamine in this example is as follows:
40mg dopamine hydrochloride was dissolved in 10mL75% ethanol, and after dopamine hydrochloride was completely dissolved, 1M ammonia was used to adjust pH =8.5. The solution was magnetically stirred at 30 ℃ for 24h. And centrifuging the reaction product at 12000rpm for 20min, and repeatedly centrifuging and washing the reaction product with deionized water for three times to obtain the poly-dopamine nano composite particles (marked as PDA).
The preparation method of the bone tumor cell targeted drug carrier in the embodiment is as follows:
the bone tumor cell targeting peptide and the polydopamine were mixed at a molar ratio (20).
The preparation method of the bone tumor cell targeted pharmaceutical composition in this embodiment is as follows:
and (2) mixing the carrier with 0.1mg/mL adriamycin dimethyl sulfoxide solution, wherein the molar ratio of the polydopamine nanoparticles to the adriamycin is 1.
In order to verify the technical effects described above, the applicant of the present application performed the following tests and characterization on the test materials in example 1.
(I) observing the reaction by Transmission Electron Microscope (TEM) to obtain M @ -P and TM @ -P nanoparticles
Respectively adding 1 mu g of M @ P and TM @ P obtained by reaction into 1mL of deionized water for dispersion, after ultrasonic treatment for 1h, respectively dropwise adding 1 mu L of the diluent on an electron microscope copper mesh, and airing the solution for later use. The M @ P and TM @ P nanoparticles obtained by the reaction were observed using a Transmission Electron Microscope (TEM), as shown in FIG. 1. As can be seen from FIG. 1, M @ P and TM @ P are uniform in size, cubic in shape, with distinct MOF structure.
(II) in vitro simulation test, scanning electron microscope element distribution
The preparation method of the NM @ P sample is as follows:
by using D 8 -KCPGGWQQIGCK-R 8 the-C polypeptide is used as a control experiment, the polypeptide structure cannot be recognized by MMP, so that the polypeptide is a bone targeting MMP non-cleavable peptide and is marked as BTNP. BTNP was mixed with the M @ p nanocomposite particles synthesized in example 1 at a molar ratio of 20. (note as NM @ P)
100 μ L of aqueous solutions of M @ -P, NM @ -P and TM @ -P, each at a concentration of 100 μ g/mL, were incubated with the hydroxyapatite sheet for 24h. Thereafter, the EDS elemental analysis image of the sample was observed by using SEM. In order to characterize the bone affinity of tm @ p, high crystallinity hydroxyapatite sheets (the major inorganic component of bone) were used in this application for in vitro bone targeting experiments. Studies have shown that the erosive bone surface is composed primarily of highly crystalline hydroxyapatite, while the new bone interface is composed primarily of amorphous hydroxyapatite. Therefore, the adoption of the high-crystallinity hydroxyapatite sheet can better simulate the bone erosion interface of bone tumor in vitro. After incubating M @ P, NM @ P and TM @ P with the hydroxyapatite sheet for 24h, EDS-mapping was used to characterize their binding ability to hydroxyapatite, and the specific characterization results are shown in FIG. 2. The surface of the NM @ P and TM @ P hydroxyapatite is combined with a large amount of Mn 2+ Significantly higher than the unmodified M @ P group, suggesting that both BTNP and BTTP have bone targeting.
(III) mouse experiment, in vivo imaging
MDA-MB-231 cells (2X 10 in 20. Mu. LPBS) 5 Individual cells) were seeded into the luminal marrow of the tibia to generate an in situ bone tumor model. Bone tumor-producing mice were intravenously injected with near infrared fluorescent molecule-labeled M @ P-Cy5.5 (30.00 mg/kg), TM @ P-Cy5.5 (30.00 mg/kg) and NM @ P-Cy5.5 (30.00 mg/kg), respectively, and imaged by small animal In Vivo (IVIS) 24h later. The mice were then sacrificed and bone tumors were isolated from the tibia. Bone tumors and tibia were also imaged by IVIS. The IVIS characterization results are shown in fig. 3. As can be seen in FIG. 3, NM @ P-Cy5.5 and TM @ P-Cy55 fluorescence signals were detected at tibial tumors, while M @ P-Cy5.5 had no fluorescence signal at tibial tumors. Further dissecting the tibial tumor, isolating the tumor from the tibia, the fluorescence of TM @ P-Cy5.5 was distributed mainly at the bone tumor, while the fluorescence of NM @ P-Cy5.5 was distributed mainly at the tibia. Experimental results prove that the bone tumor cell targeting of BTTP is realized, but BTNP which can not be identified by MMP and then sheared does not have the bone tumor cell targeting.
Nuclear magnetic resonance Imaging of (IV) small animals
M, TM and NM @ P (30.00 mg/kg) were injected into tumor-bearing mice via tail vein, respectively. MR images were taken on a Bruker 7.0T magnet equipped with Avance II hardware, equipped with 72mm quadrature transmit/receive coils, taken before and 24h after injection. The parameters for 7T MRI were: TR (repetition time) =750.0ms, te (echo time) =12.6ms, echo =1/1, fov =6.91/3.12cm, slice thickness =2mm, nex (mean) =2mm, matrix =256 × 116.
And verifying the bone tumor targeting property of BTTP, and using MRI for characterization. Mn 2+ Has MRI T1 mode contrast function. T1 modality MRI examinations were performed on bone-bearing tumor mice in groups of M @ P, NM @ P and TM @ P with a 7.0T MR scanner. T1 weighted MR was performed on 24h before and after intravenous M @ P, NM @P and TM @ P images, respectively. Analysis of the T1-weighted signal changes in tumor-associated tibia revealed (as in FIG. 4) that NM @ P observed a significantly brighter T1-weighted signal at the tibia, while TM @ P observed a brighter T1-weighted signal at the tumor. There was no significant change in tumor-associated tibial signals before and after injection of M @ P. The result shows that the T1 weighted MRI contrast agent can be used as an MRI contrast agent for bone tumors with TM @ P, and the T1 weighted MRI signal of mice injected with TM @ P is obviously enhanced, which shows that BTTP obviously enhances the bone tumor targeting of nanoparticles.
Based on the above mechanism and experimental effect, the TP formed in embodiment 3 of the present application, as a drug carrier, has a good bone targeting and bone tumor targeting effect, due to the modification of the polypeptide having bone targeting and bone tumor targeting.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which may be made by those skilled in the art without departing from the spirit and scope of the present invention as defined in the appended claims.
Sequence listing
<110> Shanghai university of traffic medical college affiliated ninth people hospital
<120> cell targeting polypeptide for treating bone tumor, preparation method and application thereof
<130> PCNDJ2010271
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Lys Cys Gln Gly Trp Ile Gly Gln Pro Gly Cys Lys
1 5 10
<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Cys Gln Gly Trp Ile Gly Gln Pro Gly Cys
1 5 10
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Gln Gly Trp Ile Gly Gln Pro Gly
1 5
<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Cys Gln Gly Trp Ile Gly Gln Pro Gly Cys Lys
1 5 10
<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Lys Cys Gln Gly Trp Ile Gly Gln Pro Gly
1 5 10
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Cys Gln Gly Trp Ile Gly Gln Pro Gly
1 5
<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Gly Trp Ile Gly Gln Pro Gly Cys Lys
1 5
<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Gly Trp Ile Gly Gln Pro
1 5
Claims (10)
1. An isolated polypeptide having the structure of formula i:
Dm-X-Rn-C is shown as formula I,
in the formula I, m is the number of aspartic acid, and m is more than or equal to 6 and less than or equal to 10; n is the number of arginine, n is more than or equal to 6 and less than or equal to 10, X is a polypeptide fragment which can be recognized and cut by MMP, and the amino acid sequence of X is selected from any one of the following:
KCQGWIGQPGCK SEQ ID NO.1，
CQGWIGQPGC SEQ ID NO.2，
QGWIGQPG SEQ ID NO.3，
CQGWIGQPGCK SEQ ID NO.4，
KCQGWIGQPG SEQ ID NO.5，
CQGWIGQPG SEQ ID NO.6。
2. the polypeptide of claim 1, wherein m is 8 and n is 8.
3. A composite particle modified by the polypeptide according to any one of claims 1 to 2, wherein the composite particle is a polydopamine or polydopamine nanocomposite particle modified by the polypeptide according to any one of claims 1 to 2; the polydopamine nano-composite particle takes a metal organic framework as an inner core and takes polydopamine as an outer layer.
4. The composite particle according to claim 3, wherein the size of the polydopamine nanocomposite particle is 80 to 200nm;
and/or the molar ratio of the polypeptide to the polydopamine or polydopamine nanocomposite particle is (5 to 100): 1;
and/or the metal organic framework is polydopamine and Mn 2+ And Co 3+ A hybrid material with intramolecular voids formed by coordination bond self-assembly.
5. The composite particle according to any one of claims 3 to 4, wherein the preparation method of the polydopamine nanocomposite particle comprises the following steps: mn (COO) 2 ·4H 2 O、K 3 [Co(CN) 6 ]And dopamine hydrochloride in the presence of an alkaline and organic solvent.
6. A method for preparing the composite particle according to any one of claims 3 to 5, comprising mixing the polypeptide with polydopamine or polydopamine nanocomposite particles.
7. Use of the polypeptide according to any one of claims 1 to 2 and the composite particle according to any one of claims 3 to 5 as a carrier for preparing a bone tumor cell targeted drug or a bone tumor treatment targeted drug.
8. A carrier of bone tumor cell targeted drugs, which is characterized in that the carrier comprises one or two of the polypeptide of any one of claims 1 to 2 and the composite particles of any one of claims 3 to 5.
9. A bone tumor cell-targeted pharmaceutical composition, comprising at least:
an active ingredient for treating bone tumor and a carrier, wherein the carrier is one or two selected from the polypeptide of any one of claims 1 to 2 and the composite particle of any one of claims 3 to 5.
10. The pharmaceutical composition according to claim 9, wherein the effective component for treating bone tumor is doxorubicin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110387572.XA CN113372412B (en) | 2021-04-09 | 2021-04-09 | Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110387572.XA CN113372412B (en) | 2021-04-09 | 2021-04-09 | Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113372412A CN113372412A (en) | 2021-09-10 |
| CN113372412B true CN113372412B (en) | 2022-10-11 |
Family
ID=77570025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110387572.XA Active CN113372412B (en) | 2021-04-09 | 2021-04-09 | Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113372412B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114425086B (en) * | 2022-01-04 | 2023-08-22 | 哈尔滨理工大学 | Preparation method of MOF-808@CREKA@HDBB nano tumor targeting vector |
| CN114699526B (en) * | 2022-04-12 | 2024-04-26 | 茂名市人民医院 | Phycocyanin mineralized nanoparticle as well as preparation method and application thereof |
| CN115429752B (en) * | 2022-09-21 | 2023-07-18 | 常熟雷允上制药有限公司 | Red sage root injection and its preparation method and application |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8993721B2 (en) * | 2008-05-14 | 2015-03-31 | Kyungpook National University Industry-Academic Cooperation Foundation | Peptides for targeting apoptotic cells and uses thereof |
| CN105294831A (en) * | 2015-10-10 | 2016-02-03 | 四川大学 | Tumor-targeting novel polypeptide |
| WO2017063542A1 (en) * | 2015-10-12 | 2017-04-20 | 复旦大学 | Stabilized a7r polypeptides, and use thereof in constructing tumor targeted therapeutic drug delivery system |
| CN109384850A (en) * | 2017-08-11 | 2019-02-26 | 复旦大学 | Overall process target polypeptide and its application in building cancer target diagnosis and treatment delivery system |
| CN109897089B (en) * | 2017-12-10 | 2023-08-22 | 复旦大学 | Integrin ligand VS polypeptide and application thereof in preparation of tumor targeting diagnosis and treatment drug delivery system |
| CN108938596B (en) * | 2018-08-03 | 2020-07-28 | 宁夏医科大学 | CPPs/NGR modified drug-loaded nano gold rod and preparation method and application thereof |
| CN109517073A (en) * | 2018-11-30 | 2019-03-26 | 北京泽勤生物医药有限公司 | A kind of fusogenic peptide of targeting therapy on tumor and its application |
| CN111821469A (en) * | 2020-07-01 | 2020-10-27 | 四川大学 | Homing targeting RSGRVSN peptide modified polyethylene glycol-polydopamine-Prussian blue composite nanoparticle and preparation method thereof |
-
2021
- 2021-04-09 CN CN202110387572.XA patent/CN113372412B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113372412A (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113372412B (en) | Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof | |
| US9642925B2 (en) | Magnetic nanoparticle formulations, methods for making such formulations, and methods for their use | |
| CN108478598B (en) | Water-soluble fullerene nano material and preparation method and application thereof | |
| Yang et al. | Preparation and properties of a novel drug delivery system with both magnetic and biomolecular targeting | |
| CN100355454C (en) | Nanometer magnetic powder-antihuman liver cancer monoclonal antibody HAb18 target medicine for magnetic thermal therapy | |
| CN1772300A (en) | Nanometer magnetic powder-anti CEA antibody targeting medicine for magnetic thermotherapy | |
| Jing et al. | Multifunctional nanoflowers for simultaneous multimodal imaging and high-sensitivity chemo-photothermal treatment | |
| Hu et al. | High-performance nanostructured MR contrast probes | |
| KR100882611B1 (en) | Low molecular water soluble chitosan nanoparticles for delivery of gene carrier modified with folate as a target ligand and preparation method thereof | |
| CN1772303A (en) | Nanometer magnetic powder-antibody targeting medicine for magneto thermical threrapy of malignant tumor | |
| CN109157662B (en) | Human serum albumin-adriamycin cross-linked substance nano-particles and application thereof | |
| CN106344937A (en) | Monolayer molybdenum disulfide-cobalt ferrite nanocomposite material as well as preparation method and application thereof | |
| CN102048694B (en) | Polypeptide-modified liver tumor-targeted nano medicine delivery system and preparation method thereof | |
| US20100323021A1 (en) | Antitumoral treatments | |
| CN107899018B (en) | CD44 targeted chondroitin sulfate-adriamycin conjugate and PLGA mixed micelle thereof | |
| Liu et al. | A high-performance imaging probe with NIR luminescence and synergistically enhanced T 1–T 2 relaxivity for in vivo hepatic tumor targeting and multimodal imaging | |
| Lin et al. | Complete separation of magnetic nanoparticles via chemical cleavage of dextran by ethylenediamine for intracellular uptake | |
| Yao et al. | Multifunctional ferritin nanocages for bimodal imaging and targeted delivery of doxorubicin into cancer cells | |
| CN110862546B (en) | Methotrexate metal coordination polymer and preparation method and application thereof | |
| Liu et al. | CXCR4 Peptide Conjugated Au-Fe 2 O 3 Nanoparticles for Tumor-targeting Magnetic Resonance Imaging | |
| Zheng et al. | Folate-conjugated magnetic nanoparticles for tumor hyperthermia therapy: in vitro and in vivo studies | |
| CN113662940B (en) | Self-assembled nano material of metformin hydrochloride and TGF-beta inhibitor | |
| CN105125549A (en) | Novel methotrexate controlled-release targeted carbon nanohorn drug loading system | |
| Zamay et al. | Aptamer-conjugated superparamagnetic ferroarabinogalactan nanoparticles for targeted magnetodynamic therapy of cancer | |
| CN114949261B (en) | Iron gadolinium nano-composite and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |